- Report
- August 2024
- 200 Pages
Global
From €2217EUR$2,490USD£1,937GBP
- Report
- December 2024
- 171 Pages
Global
From €2813EUR$3,160USD£2,458GBP
€3517EUR$3,950USD£3,073GBP
- Report
- September 2024
- 343 Pages
Global
From €5662EUR$6,360USD£4,948GBP
€7078EUR$7,950USD£6,185GBP
- Report
- April 2023
- 115 Pages
Global
From €4229EUR$4,750USD£3,695GBP
- Report
- April 2023
- 117 Pages
Global
From €4229EUR$4,750USD£3,695GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €3525EUR$3,960USD£3,081GBP
€4407EUR$4,950USD£3,851GBP
- Report
- May 2024
- 133 Pages
Global
From €4918EUR$5,524USD£4,298GBP
€5786EUR$6,499USD£5,056GBP
- Report
- January 2024
- 150 Pages
Global
From €3427EUR$3,850USD£2,995GBP
€4318EUR$4,850USD£3,773GBP
- Report
- March 2023
- 147 Pages
Global
From €4406EUR$4,949USD£3,850GBP
- Report
- September 2024
- 128 Pages
Global
From €13349EUR$14,995USD£11,666GBP
- Report
- August 2024
- 49 Pages
Global
From €3557EUR$3,995USD£3,108GBP
- Clinical Trials
- December 2023
- 2092 Pages
Global
From €2226EUR$2,500USD£1,945GBP
- Report
- January 2023
- 90 Pages
Global
From €3111EUR$3,495USD£2,719GBP
- Report
- August 2022
- 541 Pages
Global
From €2226EUR$2,500USD£1,945GBP
- Report
- May 2023
- 109 Pages
Global
From €3500EUR$4,211USD£3,166GBP
- Report
- May 2023
- 79 Pages
Global
From €3500EUR$4,211USD£3,166GBP
- Report
- January 2025
- 132 Pages
Global
From €846EUR$950USD£739GBP
- Report
- January 2025
- 132 Pages
Global
From €846EUR$950USD£739GBP

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects millions of people worldwide. It is characterized by difficulty breathing, coughing, and wheezing. COPD is typically treated with a combination of medications, including bronchodilators, inhaled corticosteroids, and antibiotics. The COPD drug market is a subset of the larger respiratory drug market, which includes drugs used to treat asthma, allergies, and other respiratory conditions.
The COPD drug market is highly competitive, with a variety of companies offering different types of medications. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, and Merck. These companies offer a range of COPD medications, including bronchodilators, inhaled corticosteroids, and antibiotics. Other companies, such as Teva Pharmaceuticals and Mylan, also offer generic versions of these medications. Show Less Read more